October 28, 2026
The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.
On Oct. 15, 2026, Octapharma USA, Inc. initiated a voluntary market withdrawal of one lot of Panzyga® (immune globulin intravenous, human-ifas) 10% liquid preparation. The withdrawal followed an increased number of hypersensitivity event reports, though no serious injuries have been reported so far. Panzyga is FDA-approved to treat PI in patients 2 years and older, chronic immune thrombocytopenia (ITP) in adults, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
Last updated: October 28, 2026